Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 April 1999Website:
http://www.eloxxpharma.comNext earnings report:
25 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 20 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
ELOX Latest News
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations
While getting kicked off an exchange typically signals about the biggest warning sign you can possibly receive, a (somewhat) rational argument exists for delisted stocks to buy. Psychologically, companies go through much anxiety doing whatever they can to stay listed in a major exchange.
Arguably the most impressive mover yesterday was a stock you have probably never heard of. Shares of Eloxx Pharmaceuticals NASDAQ: ELOX rocketed almost 100% yesterday after receiving an increased price target from Oppenheimer.
Eloxx Pharmaceuticals (NASDAQ: ELOX ) stock is falling hard on Tuesday after the company provided a weak earnings report for Q1 2023. The bad news for ELOX stock starts with its losses per share of $2.88 cents.
Senesco Technologies Inc. (ELOX) came out with a quarterly loss of $2.88 per share versus the Zacks Consensus Estimate of a loss of $2.55. This compares to loss of $5.20 per share a year ago.
What type of business is Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
What sector is Eloxx Pharmaceuticals in?
Eloxx Pharmaceuticals is in the Healthcare sector
What industry is Eloxx Pharmaceuticals in?
Eloxx Pharmaceuticals is in the Biotechnology industry
What country is Eloxx Pharmaceuticals from?
Eloxx Pharmaceuticals is headquartered in United States
When did Eloxx Pharmaceuticals go public?
Eloxx Pharmaceuticals initial public offering (IPO) was on 26 April 1999
What is Eloxx Pharmaceuticals website?
https://www.eloxxpharma.com
Is Eloxx Pharmaceuticals in the S&P 500?
No, Eloxx Pharmaceuticals is not included in the S&P 500 index
Is Eloxx Pharmaceuticals in the NASDAQ 100?
No, Eloxx Pharmaceuticals is not included in the NASDAQ 100 index
Is Eloxx Pharmaceuticals in the Dow Jones?
No, Eloxx Pharmaceuticals is not included in the Dow Jones index
When was Eloxx Pharmaceuticals the previous earnings report?
No data
When does Eloxx Pharmaceuticals earnings report?
The next expected earnings date for Eloxx Pharmaceuticals is 25 November 2024